Drug Profile
Research programme: melanoma vaccine - Immune Response BioPharma
Alternative Names: IR-222; MelanoVaxLatest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Immune Response BioPharma
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
- 13 Dec 2013 Preclinical trials in Malignant melanoma in USA (Parenteral)